The patient population, in a sense, is an astronaut six months from Earth, eating the same shelf-stable rations on day 180 that they ate on day one. Micronutrient deficiency on long-duration missions is not theoretical: it is a known clinical risk that NASA has been trying to engineer around for two decades. The standard of care today is prepackaged food, vitamin supplementation, and the occasional lettuce harvest from the Veggie and Advanced Plant Habitat units aboard the International Space Station. Fresh produce in orbit remains a garnish, not a meal.
Interstellar Lab, the California and Florida biotech founded in 2018 by Barbara Belvisi, is building toward something more ambitious: a closed-loop bioregenerative system that produces microgreens, vegetables, mushrooms, and edible insects in a single modular unit. That system, called NUCLEUS, won the $750,000 grand prize in the finale of NASA's Deep Space Food Challenge after first taking phase one and then phase two of the multi-year competition [NASA]. The win matters less for the cash than for the validation: NASA selected NUCLEUS as a credible architecture for feeding crews on missions to the Moon and Mars, where resupply is not an option.
The bet
The company sells what it calls BioPods, intelligent biospheres that grow plants autonomously, and is adapting that core technology for two very different customers [Crunchbase]. On Earth, the buyers are companies that need consistent, high-purity botanical inputs: Interstellar Lab has disclosed work with the French fragrance and flavor house Robertet on plant-based naturals, and has shown its SIRIUS unit at Climate Week NYC as a production system for the beauty industry [Interstellar Lab]. In orbit, the buyer is the emerging commercial space station market.
That second customer just got concrete. Interstellar Lab is partnering with Vast, the Long Beach company building the Haven-1 station, to fly a plant research payload called Eden 1.0 on Haven-1's first mission, currently scheduled to launch no earlier than May 2026 [Vast, April 2025; SatNews, April 2025]. Eden 1.0 is designed to conduct plant research in microgravity, the kind of data NASA and commercial operators will need before any closed-loop food system flies operationally. Vast is also positioning Haven-2 as a candidate for NASA's Commercial LEO Destinations program, the agency's plan to replace the ISS with privately operated stations [Interstellar Lab].
Why it could be big
The market shape here is unusual. There is a near-term commercial pull from Earth-side buyers who want controlled-environment agriculture for high-value botanicals, and a longer-dated but extremely well-funded pull from space agencies and commercial station operators who need life-support payloads. A company that can serve both is hedged in a way that pure space-farming startups are not.
The cap table reflects that thesis. Interstellar Lab has raised roughly $15 million in total disclosed funding, including a $5 million seed round in March 2022 [Tech Startups, March 2022]. Backers include Kima Ventures (Xavier Niel's prolific seed fund), 7percent Ventures, Auxxo, Urania Ventures, Seldor Capital, E2MC, Issart Capital, and BPI, the French public investment bank. The investor mix, French deep-tech seed funds plus a space-focused vehicle in E2MC plus state capital, fits a company that needs patient money and government relationships in equal measure.
Total disclosed funding | 15 | $M
Seed round (Mar 2022) | 5 | $M
NASA Deep Space Food prize | 0.75 | $M
The team and traction
Belvisi is the solo founder and chief executive. Before Interstellar Lab she co-founded Hardware Club in 2014 with Alexis Houssou and served as managing partner, a venture firm focused on connected hardware startups [TechCrunch, September 2015; Bloomberg]. Her earlier career ran through portfolio management at Foncière Euris, private equity at NEO Capital in London, and deep-tech venture investing starting in 2012 [Economist Impact]. She is self-taught in the engineering and architecture disciplines the company now depends on, and reportedly spent a year embedded with NASA engineers before founding Interstellar Lab [The Org]. The team is approximately 40 people across France, Texas, and Florida [Inc; NASA], with the U.S. headquarters at the Space Life Sciences Lab on Kennedy Space Center grounds in Merritt Island [Space Coast Daily, August 2024]. David Kas leads quantitative and AI work, including a reinforcement-learning approach to life-support control and a machine-learning tool called Crop Selector for space-bound BioPods [LinkedIn].
Beyond the NASA prize and the Vast partnership, the company has announced Mission Little Prince, a collaboration with the Antoine de Saint Exupéry Foundation to grow roses on the Moon [Whatfinger Business & Money, April 2026]. The Robertet partnership represents the clearest line of sight to terrestrial revenue from a named industrial customer.
The honest counterfactual
The most credible bear case is dilution of focus. Bioregenerative life support for deep-space crews and contract growing for the fragrance industry are genuinely different engineering problems, and a 40-person team serving both could find itself stretched. Closed-environment agriculture has also been a graveyard for well-funded ventures on Earth alone, where vertical-farming companies with far larger balance sheets have struggled with unit economics. The bull answer, supported by the cited evidence, is that Interstellar Lab's space work is largely funded by milestone-based prize money and partnership revenue (the NASA challenge alone contributed $750,000), while the Earth side targets high-margin botanical inputs rather than commodity leafy greens. That is a meaningfully different cost structure than warehouse lettuce.
What to watch
The next twelve months will be defined by Eden 1.0. If Vast's Haven-1 launches on its current no-earlier-than May 2026 timeline and Interstellar Lab's payload returns usable plant-growth data from microgravity, the company will have something almost no agtech startup can claim: flight heritage. That, combined with the NASA Deep Space Food Challenge win, would position it as a default vendor when NASA and commercial station operators begin specifying food and life-support payloads for CLD-era stations. A follow-on round to fund the scale-up of both BioPod manufacturing and a second-generation space payload would be the logical next financial step.
The disease state, to borrow the frame from clinical reporting, is human survival far from Earth. The standard of care is rations and supplements. Interstellar Lab is one of a small number of companies trying to change that, and for now it is doing so with NASA's money, a launch manifest, and a customer in low Earth orbit.